Lv1
20 积分 2024-11-17 加入
Skin toxicities related to Bruton tyrosine kinase inhibitors: an updated review
9小时前
待确认
Rilzabrutinib
18天前
已完结
A first‐line regimen combining Bruton's tyrosine kinase and programmed cell death protein‐1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma
18天前
已完结
Aligning patient‐reported priorities in immune thrombocytopenia with clinical and regulatory advances: Insights from rilzabrutinib
2个月前
已完结
A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study
2个月前
已关闭
Multiple sclerosis updates and the safety and efficacy of Bruton tyrosine kinase inhibitors in it: A systematic review
2个月前
已完结
Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database
4个月前
已完结
Mitochondrial ROS-dependent CD4+PD-1+T cells are pathological expansion in patients with primary immune thrombocytopenia
4个月前
已完结
Immune thrombocytopenia (ITP) - could it be part of autoimmune/inflammatory syndrome induced by adjuvants (ASIA)?
4个月前
已完结
Real-World Outcomes with Orelabrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Retrospective Study
5个月前
已完结
皖公网安备34019202002308
